infect
account
around
death
first
year
transplant
bacteri
pathogen
respons
approxim
half
infect
risk
infect
follow
lung
transplant
determin
number
factor
includ
physic
factor
denerv
allograft
result
reduc
cough
reflex
anastomot
site
stenosi
distal
infect
net
state
immunosuppressionth
result
factor
includ
host
immun
system
antireject
immunosuppress
therapi
concomit
viral
infect
cytomegaloviru
contribut
patient
risk
infect
epidemiolog
exposur
organ
includ
donorderiv
infect
commun
acquir
infect
travel
relat
infect
healthcar
associ
infect
use
prophylact
antimicrobi
agent
posttranspl
period
bacteria
defin
morpholog
shape
size
pathogen
bacteri
speci
spheric
cocci
rodshap
bacilli
may
exist
singl
cell
exampl
mani
common
bacilli
pseudomona
stenotrophomona
varieti
characterist
pattern
pneumonia
pair
lancet
shape
cocci
aureu
larg
cluster
cocci
form
bunch
grape
streptococci
long
chain
cocci
whilst
molecular
diagnost
techniqu
polymeras
chain
reaction
pcr
increasingli
import
basi
much
microbiolog
diagnosi
remain
characterist
appear
organ
glass
microscop
slide
stain
dye
varieti
condit
common
stain
includ
gram
stain
first
describ
hc
gram
still
everyday
use
ziehlneelsen
acidfast
stain
mycobacteria
modifi
ziehlneelsen
stain
nocardia
gram
stain
divid
bacteria
gram
posit
gram
neg
depend
abil
cell
wall
prevent
decolouris
stain
crystal
violet
import
rememb
bacteria
aureu
pseudomona
speci
stain
ziehlneelsen
stain
convers
mycobacteria
seen
gram
stain
cultur
techniqu
also
differ
mycobacteria
often
unabl
grow
convent
agar
plate
requir
special
growth
media
prolong
cultur
period
therefor
mycobacteri
infect
suspect
request
form
sampl
must
specifi
mycobacteri
cultur
appropri
investig
perform
laboratori
laboratori
diagnosi
import
bacteria
set
lung
transplant
summaris
aureu
common
colon
upper
respiratori
tract
skin
isol
increas
frequenc
sputum
patient
cystic
fibrosi
although
frequenc
decreas
age
aureu
acquir
donor
recipi
bacteri
flora
hospit
environ
healthcar
associ
infect
respons
wide
rang
health
careassoci
infect
ventilatorassoci
pneumonia
bactereamia
surgic
site
infect
isol
aureu
characteris
accord
suscept
methicillin
antistaphylococc
penicillin
methicillin
suscept
aureu
mssa
common
commun
acquir
infect
wherea
methicillin
resist
aureu
mrsa
occur
greater
frequenc
hospit
acquir
infect
largest
studi
aureu
follow
lung
transplant
retrospect
singl
centr
studi
conduct
year
period
aureu
infect
develop
lung
transplant
recipi
within
day
transplant
mssa
common
mrsa
proport
mrsa
infect
increas
time
pneumonia
common
infect
follow
tracheobronch
bacteremia
intrathorac
infect
skinsoft
tissu
infect
infect
patient
requir
longer
hospit
intens
care
unit
stay
p
mortal
rate
low
respect
howev
infect
patient
higher
rate
reject
acut
chronic
p
year
p
higher
mortal
p
year
p
dicloxacillin
flucloxacillin
cefazolin
cephalothin
penicillin
allerg
patient
notether
risk
anaphylaxi
patient
document
penicillin
anaphylaxi
clindamycin
often
prescrib
deep
infect
exhibit
good
tissu
penetr
howev
bacteriostat
antibiot
administ
patient
aureu
bacteraemia
follow
specialist
advic
vancomycin
appropri
therapeut
drug
monitor
tdm
teicoplanintdm
avail
centr
standard
dose
may
inadequ
especi
bacteraemia
linezolidsuperior
vancomycin
mrsa
pneumonia
toxic
may
occur
longterm
administr
unless
tdm
undertaken
isol
may
suscept
clindamycin
cotrimoxazol
doxycyclin
howev
agent
use
treat
bacteraemia
infect
control
mssa
specif
measur
requir
mrsa
patient
usual
place
contact
precaut
gown
apron
glove
care
hand
hygien
per
moment
hand
hygien
may
isol
singl
room
cohort
colonis
patient
prevent
spread
nonidentifi
colonis
patient
haemophilu
influenza
import
respiratori
pathogen
patient
cystic
fibrosi
often
caus
infect
earli
life
replac
organ
pseudomona
spp
time
contrast
patient
undergo
lung
transplant
indic
may
colon
h
influenza
stage
life
posttranspl
infect
h
influenza
rel
uncommon
least
part
wide
spread
practic
administr
azithromycin
trimethoprimsulphamethoxazol
prophylact
agent
postop
period
antimicrobi
agent
activ
h
influenza
therebi
reduc
frequenc
infect
approxim
h
influenza
isol
suscept
ampicillin
ampicillin
resist
isol
gener
suscept
augmentin
cefuroxim
third
gener
cephalosporin
cefotaxim
ceftriaxon
cephalexin
ineffect
specif
infect
control
measur
requir
standard
precaut
hand
hygien
like
h
influenza
pneumonia
import
respiratori
pathogen
uncommon
set
lung
transplant
part
impact
antimicrobi
prophylaxi
trimethoprimsulphamethoxazol
azithromycin
lung
transplant
reduct
import
compon
immun
system
serum
immunoglobulin
common
occur
lung
transplant
recipi
like
increas
risk
frequenc
sever
pneumococc
infect
pneumonia
gener
suscept
penicillin
penicillin
resist
pneumonia
pulmonari
infect
usual
success
treat
penicillin
concentr
achiev
lung
suffici
exceed
threshold
efficaci
altern
treatment
option
penicillin
resist
pneumonia
caus
mening
bloodstream
includ
third
gener
cephalosporin
vancomycin
specif
infect
control
measur
requir
standard
precaut
hand
hygien
pseudomona
aeruginosa
gram
neg
bacillu
commonli
colonis
airway
patient
cystic
fibrosi
also
found
patient
proceed
lung
transplant
exampl
chronic
obstruct
pulmonari
diseas
mani
centr
pseudomona
common
caus
posttransplant
bacteri
infect
prolong
pretranspl
therapi
varieti
antibiot
frequent
result
highli
resist
organ
colon
patient
time
transplant
laboratori
report
may
refer
mucoid
pseudomona
isol
specimen
mucoid
pseudomona
develop
certain
environment
condit
follow
infect
nonmucoid
speci
thick
polysaccharid
capsul
give
organ
wet
appear
grow
agar
plate
laboratori
importantli
render
organ
resist
immunolog
defens
mechan
phagocytosi
standard
antipseudomona
therapi
guid
laboratori
suscept
test
especi
patient
extens
prior
antibiot
exposur
suscept
test
mucoid
strain
less
reliabl
standard
strain
commonli
use
antibiot
includ
aminoglycosid
gentamicin
tobramycin
amikacin
antipseudomon
betalactam
piperacillintazobactam
ceftazidim
cefepim
ciprofloxacin
meropenem
colistin
may
occasion
requir
extrem
resist
organ
contact
precaut
gener
reserv
patient
multidrug
resist
pseudomona
aeruginosa
stenotrophomona
maltophilia
gram
neg
bacillu
increasingli
recogn
import
pathogen
airway
set
lung
transplant
organ
widespread
environ
found
soil
water
anim
plant
materi
treatment
complic
multidrug
resist
trimethoprimsulphamethoxazol
treatment
choic
although
resist
increasingli
describ
ciprofloxacin
activ
approxim
laboratori
isol
infect
control
specif
infect
control
requir
standard
precaut
hand
hygien
burkholderia
speci
gram
neg
bacilli
close
relat
pseudomona
speci
fact
previous
call
pseudomona
cepacia
sometim
see
refer
older
literatur
set
cystic
fibrosi
lung
transplant
clinic
import
speci
belong
burkholderia
cepacia
complex
bcc
group
genet
close
relat
organ
howev
recent
recognis
bcc
equal
pathogen
import
organ
includ
b
cenocepacia
previous
name
bcc
genomovar
iii
burkholderia
multivoran
previous
bcc
genomovar
account
burkholderia
cepacia
complex
isol
patient
cystic
fibrosi
one
fear
organ
burkholderia
cenocepacia
aggress
pathogen
transmiss
patient
caus
epidem
recent
studi
suggest
b
cenocepacia
associ
poor
outcom
contraind
transplant
mani
centr
therefor
accur
detect
identif
burkholderia
speci
prior
transplant
absolut
essenti
fals
posit
result
lead
exclus
transplant
wait
list
wherea
fals
neg
result
lead
poor
transplant
outcom
possibl
cross
infect
patient
appropri
infect
control
measur
put
place
standard
treatment
elimin
bcc
erad
bcc
extrem
difficult
mani
speci
bcc
particularli
b
cenocepacia
intrins
resist
via
varieti
resist
mechan
numer
antimicrobi
agent
includ
aminoglycosid
gentamicin
tobramycin
antipseudomon
betalactam
antibiot
piperacillintazobactam
cefepim
ceftazidim
colistin
rapid
develop
resist
may
occur
therapi
studi
larg
number
bcc
isol
strain
burkholderia
cepacia
complex
isol
cystic
fibrosi
patient
test
resist
avail
antimicrobi
agent
demonstr
isol
activ
agent
minocyclin
meropenem
ceftazidim
inhibit
strain
respect
use
combin
antimicrobi
therapi
overcom
issu
usual
success
bcc
spread
suscept
patient
person
person
contact
contact
contamin
surfac
object
exposur
bcc
environ
contact
precaut
isol
see
mrsa
may
implement
hospit
altern
patient
colonis
bcc
hous
next
immunosuppress
patient
mycobacteria
bacteria
form
genu
within
phylum
actinobacteria
speci
identifi
pathogen
potenti
caus
infect
human
mycobacteria
slender
curv
rod
unlik
bacteria
acid
fast
see
preced
section
addit
resist
alkali
dehydr
mean
surviv
long
period
environ
cell
wall
contain
complex
wax
glycolipid
multipl
slowli
special
media
clinic
isol
take
week
grow
base
growth
rate
catalas
niacin
product
pigment
light
dark
condit
mycobacteria
classifi
mycobacterium
tuberculosi
complex
tuberculosi
bovi
africanum
microtii
nontubercul
mycobacterium
ntm
molecular
techniqu
eg
pcr
readili
differenti
tuberculosi
transmit
person
person
incid
transplant
recipi
much
higher
gener
popul
common
caus
transplant
popul
reactiv
latent
infect
caus
includ
unrecognis
transmiss
donor
lung
donorderiv
especi
countri
tb
endem
primari
infect
transplant
median
time
infect
lung
transplant
month
earlier
renal
transplant
recipi
donorderiv
infect
usual
occur
earlier
often
within
first
month
postlung
transplant
risk
factor
includ
prior
resid
endem
countri
histori
untreat
tb
chest
xray
show
evid
old
heal
tb
augment
immunosuppress
reject
use
tcell
deplet
agent
immunosuppress
recipi
age
lung
common
site
infect
extrapulmonari
dissemin
tb
occur
unusu
present
eg
skin
ulcer
abscess
tenosynov
fever
common
present
complaint
night
sweat
weight
loss
instead
classic
caviti
seen
chest
xray
immunocompet
patient
lung
transplant
recipi
focal
infiltr
miliari
pattern
nodul
pleural
effus
common
fig
diagnosi
activ
tb
challeng
lung
transplant
recipi
sputum
sampl
commonli
stain
cultur
neg
bronchoalveolar
lavag
bal
fluid
sent
acid
fast
bacilli
afb
stain
fig
cultur
ideal
pcr
test
use
decreas
time
diagnosi
given
cultur
slow
grow
biopsi
skin
lesion
abscess
soft
tissu
lesion
access
extrapulmonari
site
afb
stain
cultur
histolog
andor
pcr
assist
diagnosi
extrapulmonari
tb
guidelin
exist
treatment
activ
tb
howev
specif
thing
note
lung
transplant
set
rifamycinbas
regimen
rifampicin
common
drug
use
group
strongli
prefer
steril
capac
abil
prevent
emerg
resist
rifamycin
interact
immunosuppress
agent
dose
adjust
requir
initi
cessat
close
monitor
level
immunosuppress
drug
whilst
receiv
rifamycin
centr
prefer
rifabutin
use
transplant
set
less
impact
drug
metabol
rifampicin
localis
nonsever
infect
suspicion
isoniazid
resist
fluoroquinolon
could
substitut
rifamycin
durat
extend
month
depend
number
drug
use
otherwis
rifamycin
agent
use
regimen
minimum
durat
month
expert
prefer
minimum
month
transplant
set
longer
treatment
requir
sever
dissemin
infect
infect
involv
central
nervou
system
andor
bone
joint
pulmonari
diseas
ongo
afb
detect
sputum
month
streptomycin
use
lung
transplant
set
associ
highrisk
nephrotox
immunosuppress
agent
use
prevent
reject
may
requir
minim
dose
reduct
immun
reconstitut
inflammatori
syndrom
iri
occur
even
immunosuppress
agent
dosereduc
antitb
treatment
revers
immunosuppress
effect
tb
screen
latent
tb
prior
exposur
tuberculosi
reactiv
caus
clinic
diseas
need
perform
pretranspl
lung
transplant
candid
two
test
avail
name
tuberculin
skin
test
tst
interferongamma
releas
assay
igra
igra
use
centr
screen
algorithm
avail
risk
reactiv
sever
infect
increas
transplant
recipi
annual
risk
activ
tb
posit
tst
good
argument
latent
tb
treatment
optim
time
latent
tb
treatment
pretranspl
latent
tb
treat
initi
boost
tst
produc
indur
mm
posit
igra
prior
histori
untreat
latent
tb
receipt
organ
donor
known
untreat
latent
tb
isoniazid
oral
pyridoxin
treatment
choic
low
risk
toxic
rifampicin
week
isoniazid
combin
rifapentin
week
altern
regimen
pretransplant
drug
interact
alreadi
state
persontoperson
transmiss
tb
occur
major
rout
inhal
airborn
particl
number
factor
increas
risk
transmiss
airborn
particl
includ
presenc
untreat
activ
pulmonari
laryng
tb
cavitari
diseas
smear
posit
short
time
posit
tuberculosi
cultur
number
procedur
also
increas
risk
dispers
airborn
particl
includ
intub
bronchoscopi
patient
extrapulmonari
tb
contagi
howev
concomit
pulmonari
laryng
tb
need
exclud
firstli
immunocompromis
patient
extrapulmonari
tb
presum
pulmonari
tb
proven
otherwis
numer
intern
nation
tb
control
guidelin
hospit
base
infect
control
program
tb
tb
suspect
untreat
patient
must
manag
airborn
isol
room
neg
pressur
ventil
mask
must
worn
healthcar
worker
contact
patient
patient
hesh
leav
room
tb
exclud
patient
remov
isol
patient
confirm
tb
isol
discontinu
patient
receiv
treatment
demonstr
clinic
respons
three
neg
afb
smear
sputum
close
liaison
institut
infect
control
team
essenti
case
suspect
untreat
tb
common
ntm
affect
lung
transplant
recipi
includ
avium
complex
kansasii
abscessu
environment
organ
infect
usual
occur
via
acquisit
environment
reservoir
person
person
transmiss
healthcareassoci
infect
contamin
medic
devic
occur
persontoperson
transmiss
describ
abscessu
risk
factor
infect
includ
cystic
fibrosi
underli
diseas
isol
ntm
particularli
abscessu
pretranspl
use
rabbit
antithymocyt
globulin
median
time
onset
later
compar
tb
year
lung
commonli
affect
cutan
soft
tissu
dissemin
infect
seen
especi
abscessu
chelona
kansasii
dissemin
diseas
constitut
symptom
eg
sweat
tired
weight
loss
predomin
common
radiolog
featur
seen
fibrocavitari
cavitari
nodul
bronchiectasi
treeinbud
larg
opac
cm
diagnosi
challeng
environment
organ
difficult
determin
whether
isol
organ
reflect
contamin
colon
true
infect
guidelin
diagnosi
exist
ntm
factor
organ
burden
specif
speci
clinic
sign
symptom
radiolog
featur
need
consid
determin
infect
categori
whether
treat
treatment
similar
immunocompet
popul
multidrug
regimen
use
see
tabl
howev
similar
tb
specif
point
need
consid
transplant
set
suscept
test
perform
direct
initi
mainten
regimen
clarithromycin
increas
serum
level
calcineurin
inhibitor
rapamycin
agent
via
cytochrom
cyp
pathway
initi
cessat
clarithromycin
immunosuppress
agent
may
need
dose
adjust
close
monitor
immunosuppress
concentr
requir
issu
outlin
rifamycin
use
tb
treatment
also
appli
treatment
ntm
durat
treatment
longer
immunocompet
popul
minimum
usual
month
last
posit
cultur
lifelong
suppress
therapi
may
need
patient
reduct
immunosuppress
need
consid
surgic
resect
may
requir
larg
abscess
present
larg
burden
diseas
focal
diseas
respond
therapi
patient
toler
therapi
abscessu
particular
problem
lung
transplant
set
increas
incid
caus
dissemin
infect
postlung
transplant
difficult
erad
also
resist
mani
avail
antimicrobi
agent
drugrel
toxic
detect
postlung
transplant
treatment
complic
prolong
centr
isol
abscessu
lung
transplant
candid
consid
strong
rel
contraind
transplant
centr
determin
transplant
patient
pretranspl
isol
abscessu
possibl
precaut
outlin
tabl
current
expert
opinion
indic
transplant
pretranspl
isol
abscessu
decid
casebycas
basi
ntm
ubiquit
environ
transmiss
usual
environment
sourc
addit
ntm
resist
chlorin
abil
form
biofilm
result
infect
control
measur
direct
ensur
adequ
disinfect
hospit
equip
rigor
repeat
surfac
clean
highqual
water
suppli
ongo
environment
surveil
hospit
set
close
liaison
institut
infect
control
engin
team
critic
prevent
outbreak
ntm
particularli
set
construct
evid
literatur
abscessu
associ
persontoperson
transmiss
studi
indic
may
case
care
assess
institut
epidemiolog
assist
decid
patient
abscessu
requir
airborn
isol
simpli
rigor
clean
environ
recent
chimera
contamin
heatercool
unit
use
cardiac
surgeri
report
result
case
surgicalsit
dissemin
infect
worldwid
new
enhanc
decontamin
strategi
develop
ongo
surveil
requir
ensur
remain
effect
nocardia
ubiquit
saprophyt
gramposit
bacteria
belong
aerob
actinomycet
group
partial
acidfast
rod
grow
slowli
branch
chain
resembl
fungal
hypha
speci
infect
human
caus
nocardia
asteroid
sensu
stricto
n
farcinica
n
nova
n
brasiliensi
infect
nocardia
increas
lung
transplant
recipi
whilst
widespread
throughout
world
infect
nocardia
highest
frequenc
dri
windi
climat
facilit
aerosolis
dispers
infect
mostli
occur
first
year
lung
transplant
rare
within
first
month
unless
donorderiv
infect
risk
factor
includ
corticosteroid
particularli
preced
month
augment
immunosuppress
high
median
calcineurin
inhibitor
level
preced
day
rituximab
use
hypogammaglobulinaemia
also
associ
increas
risk
develop
nocardia
infect
use
alemtuzumab
treatment
allograft
reject
inhal
common
rout
infect
therefor
lung
commonli
affect
dissemin
organ
particularli
skin
central
nervou
system
cn
report
case
skin
also
infect
direct
inocul
especi
lung
transplant
recipi
involv
outdoor
activ
common
sign
symptom
fever
weight
loss
cough
pleurit
chest
pain
dyspnoea
chest
imag
frequent
show
irregular
nodular
lesion
may
cavitari
fig
featur
includ
diffus
infiltr
consolid
associ
pleural
effus
diagnosi
microscopi
cultur
histolog
examin
respiratori
specimen
particularli
bronchoalveolar
lavag
fluid
bal
biopsi
tissu
eg
skin
brain
tissu
nocardia
grow
nonselect
media
form
characterist
white
chalki
coloni
suspicion
infect
may
nocardia
inform
diagnost
laboratori
specimen
requir
longer
incub
growth
nocardia
sampl
mix
growth
multipl
organ
particularli
sputum
nocardia
may
obscur
select
media
use
improv
yield
nocardia
growth
eg
thayermartin
nocardia
characterist
featur
gram
stain
see
fig
tissu
nocardia
appear
gram
posit
branch
bead
rod
surround
pyogen
inflammatori
reaction
import
determin
speci
suscept
profil
differ
speci
differ
suscept
profil
inform
use
determin
treatment
regimen
antibiot
mainstay
treatment
site
burden
infect
speci
potenti
drugdrug
interact
determin
antimicrobi
regimen
use
treatment
mild
pulmonari
infectiontrimethoprimsulfamethoxazol
tmpsmx
week
sever
pulmonari
infect
cn
involv
parenter
treatment
tmpsmx
plu
amikacin
cn
infectionparenter
treatment
tmpsmx
plu
imipenem
multiorgan
infect
includ
cnsintraven
iv
amikacin
ad
regimen
iv
tmpsmx
imipenem
meropenem
may
use
instead
imipenem
former
less
like
precipit
seizur
activ
sensit
meropenem
must
demonstr
laboratori
use
linezolid
excel
vitro
activ
nocardia
use
success
treatment
therefor
linezolid
may
use
part
multidrug
regimen
patient
tmpsmx
allergi
desensitis
perform
possibl
parenter
treatment
continu
week
follow
oral
therapi
month
oral
agent
commonli
use
includ
tmpsmx
minocyclin
andor
amoxicillinclavulan
surgeri
may
requir
case
cerebr
nocardiosi
larg
soft
tissu
abscess
respond
treatment
empyema
mediastin
fluid
collect
pulmonari
nocardiosi
complic
pericard
consider
given
reduc
immunosuppress
especi
case
sever
diseas
progress
antimicrobi
treatment
indefinit
secondari
prophylaxi
also
recommend
immunosuppress
fulli
revers
report
persontoperson
transmiss
nocardia
literatur
nocardia
ubiquit
environment
organ
acquisit
mostli
environment
sourc
similar
ntm
infect
control
measur
hospit
set
nocardia
direct
disinfect
equip
surfac
ensur
highqual
water
suppli
ongo
surveil
requir
prevent
outbreak
particularli
set
construct
fungal
infect
signific
problem
lung
transplant
recipi
occur
caus
death
infect
major
infect
caus
aspergillu
candida
speci
cryptococcu
third
common
caus
fungal
infect
fungi
caus
mucormycosi
eg
rhizopu
speci
scedosporium
fusarium
emerg
associ
high
mortal
rate
thu
increas
emphasi
place
earli
recognit
diagnosi
treatment
histoplasma
coccidioid
blastomyc
speci
import
live
previous
resid
visit
endem
area
pneumocysti
jirovecii
whilst
infrequ
caus
signific
morbid
mortal
risk
factor
infect
similar
describ
bacteri
infect
addit
fungal
infect
implic
trigger
develop
chronic
reject
chronic
lung
allograft
dysfunct
clad
fungi
major
problem
lung
transplant
recipi
import
think
fungi
lung
transplant
recipi
suspect
infect
overestim
earli
diagnosi
treatment
critic
optimis
outcom
prophylaxi
may
reduc
impact
fungal
infect
lung
transplant
recipi
issu
drug
intoler
drugdrug
interact
emerg
resist
may
complic
treatment
reduc
overal
efficaci
fungi
singl
cell
complex
multicellular
organ
fungi
mainli
found
soil
dead
plant
matter
divid
yeast
multicellular
filament
mould
dimorph
fungi
yeast
small
lemonshap
singl
cell
around
size
red
blood
cell
multipli
bud
daughter
cell
origin
parent
cell
multicellular
filament
mould
made
fine
thread
known
hypha
grow
hyphal
tip
divid
repeatedli
along
length
creat
long
branch
chain
hyphal
branch
grow
air
spore
form
aerial
branch
spore
carri
wind
rain
insect
new
habitat
germin
start
grow
produc
new
hypha
process
infect
mimick
immunosuppress
individu
conidia
spore
inhal
impair
immun
defenc
mechan
conidia
spore
germin
uncontrol
hyphal
growth
occur
dimorph
fungi
fungi
exist
yeast
mould
prime
exampl
dimorph
fungu
penicillium
marneffei
human
pathogen
exist
mould
room
temperatur
yeast
human
bodi
temperatur
aspergillu
fumigatu
common
aspergillu
speci
speci
caus
infect
lung
transplant
set
includ
flavu
terreu
niger
nidulan
import
identifi
terreu
differ
suscept
profil
aspergillu
speci
resist
amphotericin
b
aspergillu
speci
commonli
caus
type
infect
lung
transplant
recipi
aspergillu
colonis
tracheobronchi
aspergillosi
invas
pulmonari
aspergillosi
ipa
also
known
aspergillu
pneumonia
dissemin
invas
aspergillosi
ia
aspergillu
colon
defin
detect
aspergillu
respiratori
secret
cultur
pcr
detect
aspergillu
galactomannan
cell
wall
protein
absenc
symptom
lesion
airway
seen
bronchoscopi
new
chang
seen
chest
xray
comput
tomographi
ct
scan
aspergillu
colon
detect
pretranspl
patient
commonli
cystic
fibrosi
cf
patient
risk
factor
posttranspl
ipa
clad
posttranspl
colon
found
centr
give
antifung
agent
lung
transplant
recipi
immedi
posttranspl
month
minim
aspergillu
colon
complic
use
univers
prophylaxi
time
aspergillu
colonis
lengthen
month
month
postlung
transplant
centr
give
antifung
treatment
month
aspergillu
detect
known
preemptiv
strategi
known
strategi
best
tracheobronchi
aspergillosi
defin
detect
aspergillu
respiratori
secret
cultur
pcr
detect
aspergillu
galactomannan
new
lesion
demonstr
bronchoscopi
includ
patch
red
erythema
ulcer
necrosi
pseudomembran
chang
detect
chest
xray
ct
scan
patient
may
asymptomat
may
present
symptom
fever
cough
wheez
andor
hemoptysi
occur
major
patient
first
month
postlung
transplant
import
tracheobronchi
aspergillosi
lung
transplant
recipi
risk
progress
ipa
dissemin
ia
treatment
choic
voriconazol
altern
agent
includ
amphotericin
b
posaconazol
itraconazol
combin
nebul
amphotericin
b
direct
local
effect
repeat
bronchoscop
debrid
particularli
larg
amount
necrot
debri
stent
occasion
requir
maintain
patent
airway
durat
treatment
depend
sever
initi
infect
degre
immunosuppress
respons
therapi
given
lesion
complet
heal
potenti
lifelong
bronchial
anastomot
involv
proven
ipa
defin
evid
parenchym
lung
tissu
invas
aspergillu
hypha
posit
cultur
steril
lung
tissu
alon
sign
symptom
fever
abnorm
white
cell
count
new
onset
purul
sputum
chang
charact
quantiti
sputum
respiratori
secret
new
onset
worsen
cough
dyspnoea
tachypnoea
pleural
rub
crackl
bronchial
breath
sound
probabl
ipa
defin
signssymptom
new
progress
persist
infiltr
consolid
cavit
nodul
detect
aspergillu
respiratori
secret
cultur
pcr
detect
aspergillu
galactomannan
singl
posit
bronchoalveolar
lavag
bal
posit
sputum
fig
averag
time
develop
month
dissemin
ia
respiratori
diseas
associ
infect
sinus
orbit
central
nervou
system
cn
site
aspergillu
rare
caus
infect
includ
skin
bone
eye
endophthalm
intraabdomin
caviti
retroperitoneum
eg
abscess
pericardium
voriconazol
treatment
choic
echinocandin
anidulafungin
caspofungin
micafungin
ad
synergi
extens
diseas
unwel
eg
hypox
present
treatment
dissemin
diseas
ipa
ipa
treatment
continu
complet
resolut
import
rememb
give
voriconazol
azol
antifung
agent
lung
transplant
recipi
signific
interact
immunosuppress
eg
tacrolimu
cyclosporin
sirolimu
dose
adjust
immunosuppress
requir
initi
cessat
voriconazol
azol
regular
monitor
serum
immunosuppress
level
requir
specif
infect
control
measur
requir
common
infect
type
seen
candida
speci
candidaemia
infect
bloodstream
fig
common
first
month
posttranspl
usual
relat
recent
surgeri
intens
care
unit
stay
broadspectrum
antibiot
use
peritranspl
tissu
infect
also
occur
includ
infect
pleural
effus
pleural
space
infect
infect
incis
site
bronchial
anastomot
site
infect
candida
speci
frequent
isol
mouth
pharynx
sputum
bal
specimen
almost
never
spread
invad
lung
tissu
univers
prophylaxi
target
candida
speci
first
month
posttranspl
shown
effect
howev
univers
prophylaxi
may
associ
emerg
resist
candida
strain
candidaemia
manifest
fever
sever
sepsi
eg
hypotens
tachycardia
requir
inotrop
support
invas
candidiasi
relat
site
infect
exampl
dissemin
skin
invas
candidiasi
caus
skin
pustul
eye
result
endophthalm
blood
cultur
still
goldstandard
diagnosi
candidaemia
therefor
blood
cultur
requir
patient
candidaemia
suspect
patient
invas
candidiasi
biopsi
relev
tissu
stain
cultur
histolog
examin
use
centr
access
betadglucan
test
noncultur
base
assay
detect
cell
wall
protein
candida
speci
use
addit
test
addit
blood
cultur
biopsi
patient
particularli
intraabdomin
candidiasi
echinocandin
liposom
amphotericin
b
treatment
candidaemia
seriou
candida
infect
candida
detect
sensit
profil
known
antifung
therapi
alter
isol
sensit
fluconazol
chang
agent
recommend
candida
caus
symptomat
infect
urinari
tract
echinocandin
recommend
poor
penetr
urinari
tract
set
fluconazol
isol
sensit
amphotericin
b
combin
isol
fluconazoleresist
recommend
specif
infect
control
requir
cryptococcu
caus
infect
lung
transplant
recipi
common
site
cryptococc
infect
lung
fig
dissemin
infect
also
occur
predilect
central
nervou
system
skin
involv
includ
cellul
infect
transmit
donor
lung
also
describ
median
time
infect
onset
day
addit
usual
diagnost
test
cultur
biopsi
cryptococc
antigen
assay
use
sensit
specif
use
monitor
diseas
treatment
respons
pretranspl
cryptococcosi
describ
contraind
transplant
long
diseas
control
achiev
posit
cultur
cryptococc
antigen
level
declin
fluconazol
continu
throughout
transplant
procedur
minimum
month
posttransplant
immun
reconstitut
inflammatori
syndrom
iri
common
treatment
cryptococc
infect
manifest
appar
flare
antifung
agent
use
depend
site
burden
infect
indic
diagnosisexclus
cn
diseas
ct
scan
mri
scan
head
lumbar
punctur
cultur
cryptococc
antigen
test
ct
chest
determin
extent
diseas
critic
import
cn
infect
dissemin
infect
sever
lung
diseaseliposom
amphotericin
b
minimum
week
follow
fluconazol
high
dose
week
fluconazol
lower
dose
month
year
recommend
small
volum
pulmonari
diseasefluconazol
alon
month
recommend
specif
infect
control
requir
common
manifest
pulmonari
infect
infect
cn
sinus
gastrointestin
infect
like
ingest
also
describ
cumul
incid
account
fungal
infect
risk
factor
infect
includ
renal
failur
diabet
prior
voriconazol
andor
caspofungin
use
mucormycosi
particularli
associ
tissu
infarct
necrosi
due
invas
tissu
blood
vessel
grow
hypha
fig
fungi
also
spread
rapidli
along
tissu
plane
factor
contribut
high
mortal
rate
seen
infect
view
aggress
natur
fungu
high
mortal
rate
treatment
requir
multiprong
approach
antifung
therapi
firstlin
therapi
liposom
amphotericin
b
caspofungin
ad
infect
sever
posaconazol
isavuconazol
given
mainten
therapi
patient
intoler
liposom
amphotericin
b
surgic
debrid
necrot
tissu
fig
reduct
immunosuppress
revers
underli
factor
eg
diabet
mellitu
specif
infect
control
measur
requir
scedosporium
environment
organ
recognis
worldwid
higher
incid
specif
geograph
area
spain
middl
east
australia
common
fungu
flood
tsunami
tornado
result
risk
transmiss
donor
drown
commonli
isol
cf
patient
pretranspl
risk
factor
invas
scedosporium
diseas
posttranspl
includ
pretranspl
colonis
prior
receipt
amphotericin
b
augment
immunosuppress
scedosporium
prone
dissemin
detect
blood
cultur
unlik
mould
aspergillu
lung
transplant
recipi
scedosporium
mainli
caus
colonis
invas
infect
occur
common
clinic
manifest
invas
diseas
includ
pneumonia
mediastin
fungaemia
dissemin
diseas
progress
invas
diseas
like
pretranspl
isol
thu
scedosporium
isol
prior
transplant
treat
scedosporium
innat
resist
mani
avail
antifung
agent
includ
amphotericin
b
apiospermum
sensit
azol
antifung
agent
particularli
voriconazol
combin
voriconazol
terbinafin
may
option
prolifican
known
lomentospora
prolifican
specif
infect
control
measur
requir
fusarium
account
invas
fungal
diseas
solid
organ
transplant
patient
lung
transplant
recipi
commonli
affect
like
scedosporium
whilst
fusarium
occur
worldwid
higher
incid
countri
brazil
incid
fusarium
second
aspergillu
infect
usual
occur
within
year
transplant
commonli
affect
lung
outcom
poor
mortal
rate
voriconazol
effect
agent
specif
infect
control
measur
requir
histoplasma
endem
state
border
ohio
river
valley
lower
mississippi
river
usa
also
detect
montana
idaho
countri
region
isol
includ
canada
mexico
central
south
america
part
eastern
southern
europ
africa
eastern
asia
australia
pulmonari
dissemin
infect
common
manifest
posttranspl
infect
rang
asymptomat
sever
diagnosi
made
use
combin
serolog
antigen
antibodi
cultur
respiratori
secret
biopsi
histolog
examin
affect
tissu
routin
screen
pretranspl
recommend
serial
monitor
administr
prophylaxi
recommend
activ
infect
prior
transplant
mild
diseaseitraconazol
sever
infectionamphotericin
b
infect
control
specif
infect
control
measur
requir
coccidioid
fungi
endem
southwest
unit
state
particularli
san
joaquin
valley
sonoran
desert
southern
california
arizona
northern
mexico
lung
transplant
recipi
fungi
caus
sever
pneumonia
dissemin
infect
dissemin
infect
commonli
character
skin
bone
joint
lesion
andor
mening
involv
diagnosi
establish
serolog
test
cultur
histopatholog
pretranspl
assess
requir
includ
detail
past
histori
histori
resid
travel
endem
area
requir
evalu
serolog
test
chest
xray
transplant
candid
past
infect
requir
assess
specialist
infecti
diseas
physician
clearanc
transplant
case
activ
infect
transplant
defer
infect
quiescent
radiolog
clinic
serolog
focal
pneumonia
treat
fluconazol
diffus
diseas
treat
initi
amphotericin
b
clinic
respons
follow
fluconazol
itraconazol
coccidioid
mening
treat
fluconazol
specif
infect
control
measur
requir
blastomyc
endem
part
eastern
north
america
particularli
northern
ontario
southeastern
manitoba
quebec
south
st
lawrenc
river
part
appalachian
mountain
interconnect
eastern
mountain
chain
west
bank
lake
michigan
state
wisconsin
entir
mississippi
river
includ
valley
major
tributari
eg
ohio
river
also
occur
africa
arabian
peninsula
indian
subcontin
similar
histoplasma
coccidioid
caus
pneumonia
skin
involv
verruc
wartlik
lesion
also
common
transplant
recipi
diagnosi
made
cultur
sputum
bal
tissu
histopatholog
examin
biopsi
tissu
pretranspl
assess
includ
symptom
assess
chest
radiographi
live
endem
area
prophylaxi
given
case
case
basi
liposom
amphotericin
b
clinic
improv
follow
oral
itraconazol
specif
infect
control
measur
requir
pneumocysti
jirovecii
previous
classifi
protozoan
modern
molecular
techniqu
recent
reclassifi
fungu
previous
name
p
carinii
infect
rat
renam
p
jirovecii
speci
infect
human
prophylaxi
univers
administ
solid
organ
transplant
recipi
develop
p
jirovecii
pneumonia
pjp
highest
incid
occur
lung
heartlung
transplant
recipi
centr
administ
pjp
prophylaxi
result
case
seen
import
risk
factor
pjp
corticosteroid
use
combin
immunosuppress
agent
good
data
dose
durat
corticosteroid
decid
give
prophylaxi
period
highest
risk
first
month
post
lung
transplant
centr
recommend
indefinit
prophylaxi
previous
patient
present
respiratori
failur
fever
dri
cough
awar
signific
infect
increas
sensit
diagnost
test
develop
diagnosi
made
earlier
diseas
mild
indol
less
sever
cough
dyspnoea
chest
xray
ct
scan
thorax
usual
demonstr
diffus
bilater
infiltr
import
make
microbiolog
diagnosi
obtain
respiratori
specimen
induc
sputum
ideal
bal
best
lung
biopsi
rare
requir
best
test
pcr
although
sensit
fals
posit
result
occur
serum
betadglucan
test
may
use
adjunct
avail
like
treatment
pjp
firstlin
agent
prophylaxi
tmpsmp
lower
dose
doublestrength
tablet
time
week
singlestrength
tablet
daili
altern
includ
dapson
atovaquon
aerosol
pentamidin
sever
cluster
outbreak
pjp
report
particularli
renal
transplant
patient
cluster
outbreak
persontoperson
transmiss
postul
caus
consequ
hospitalis
patient
pjp
place
room
immunocompromis
patient
otherwis
standard
precaut
appli
review
clearli
illustr
fungi
major
problem
lung
transplant
recipi
import
think
fungi
lung
transplant
recipi
suspect
infect
underestim
earli
diagnosi
treatment
critic
optimis
outcom
prophylaxi
may
reduc
impact
fungal
infect
lung
transplant
recipi
issu
drug
intoler
drugdrug
interact
emerg
resist
may
complic
reduc
overal
efficaci
multicentr
research
requir
determin
optim
prophylact
strategi
lung
transplant
recipi
virus
organ
much
smaller
bacteria
unabl
detect
routin
microscopi
abl
surviv
replic
within
live
cell
use
chemic
machineri
cell
reproduc
virus
contain
either
deoxyribonucl
acid
dna
ribonucl
acid
rna
import
dna
virus
set
transplant
includ
herpesviru
famili
whilst
rna
virus
includ
signific
respiratori
pathogen
viral
infect
either
primari
follow
reactiv
latent
viru
remain
import
caus
morbid
mortal
follow
lung
transplant
viral
cultur
extrem
labori
difficult
restrict
specialist
laboratori
increasingli
diagnosi
viral
infect
made
pcr
peripher
blood
affect
tissu
pcr
avail
member
herpesviru
famili
list
member
herpesviru
famili
caus
oral
genit
ulcer
occasion
caus
dissemin
infect
particularli
immunocompromis
host
rule
caus
oral
infect
genit
ulcer
wherea
respons
oral
infect
genit
infect
infect
may
primari
sever
reactiv
site
latenc
neuron
incid
prior
infect
increas
age
vari
accord
socioeconom
statu
race
countri
resid
gener
popul
antibodi
therefor
risk
reactiv
common
manifest
lung
transplant
recipi
mucocutan
ulcer
involv
either
oral
caviti
genit
tract
less
commonli
pneumonia
hepat
enceph
may
result
viral
reactiv
introduct
acyclovir
mark
first
highli
effect
antivir
therapi
result
signific
reduct
morbid
mortal
posttranspl
hsv
infect
incid
fallen
dramat
sinc
ganciclovir
anticmv
agent
activ
hsv
wide
use
prophylaxi
cmv
infect
transplant
set
acyclovirvalaciclovirfamciclovir
suppress
therapi
may
appropri
frequent
recurr
develop
resist
viru
uncommon
standard
precaut
appli
patient
activ
hsv
lesion
howev
contact
precaut
may
appli
healthcar
set
lesion
cover
day
post
initi
treatment
crust
occur
hsv
dissemin
contact
precaut
requir
lesion
dri
crust
immunocompromis
staff
care
patient
infect
staff
high
risk
clinic
area
requir
urgent
review
leav
redeploy
vzv
primari
infect
result
chicken
pox
viru
lay
dormant
neural
tissu
prior
reactiv
shingl
particular
period
immunosuppress
shingl
may
follow
singl
nerv
pathway
dermatom
may
involv
multipl
dermatom
viru
may
dissemin
involv
varieti
organ
includ
liver
lung
brain
spinal
cord
approxim
adult
australia
unit
state
antibodi
vzv
indic
prior
infect
howev
incid
antibodi
posit
vari
geograph
area
incid
lower
tropic
region
patient
antibodi
vzv
consid
vaccin
prior
transplant
vaccin
live
vaccin
administ
transplant
insuffici
safeti
data
immunosuppress
transplant
recipi
high
dose
acyclovirvalaciclovirfamciclovir
ganciclovir
potenti
role
zoster
immun
globulin
contact
precaut
patient
activ
vzv
lesion
day
postiniti
treatment
crust
occur
ebv
caus
agent
infecti
mononucleosi
glandular
fever
common
infect
gener
popul
also
associ
develop
two
cancer
nasopharyng
carcinoma
burkitt
lymphoma
like
herpesvirus
ebv
associ
latent
infect
case
ebv
b
lymphocyt
blood
lymphoid
tissu
set
scene
lymphoprolif
disord
set
transplant
ebv
clearli
establish
role
pathogenesi
post
transplant
lymphoprolif
disord
ptld
case
associ
ebv
latent
infect
ptld
spectrum
diseas
caus
abnorm
prolifer
lymphoid
cell
clinic
manifest
vari
asymptomat
tissu
infiltr
andor
focal
mass
varieti
organ
figur
petct
scan
patient
ptld
demonstr
widespread
involv
occur
diagnosi
made
excision
biopsi
histolog
examin
high
level
ebv
dna
measur
pcr
peripher
blood
provid
support
evid
reduc
level
immunosuppress
good
data
support
role
antivir
therapi
acyclovir
ganciclovir
immunomodulatori
agent
anti
rituximab
resect
localis
lesion
specif
precaut
requir
cmv
infect
defin
detect
cmv
replic
usual
pcr
detect
cmv
dna
rna
plasma
whole
blood
regardless
clinic
present
symptom
herpesvirus
cmv
infect
may
effect
cmv
infect
may
due
either
direct
tissu
damag
varieti
organ
eg
coliti
indirect
effect
graft
immun
system
eg
induc
clad
figur
demonstr
owl
eye
appear
cmv
inclus
bodi
bowel
patient
cmv
enter
two
approach
prevent
cmv
diseas
prophylaxi
strategyprescrib
anticmv
drug
defin
period
transplant
usual
month
preemptiv
therapytreat
anticmv
drug
plasma
blood
cmv
pcr
becom
posit
regular
monitor
choic
strategi
vari
transplant
centr
part
determin
abil
rapidli
regularli
perform
cmv
pcr
blood
plasma
set
lung
transplant
prophylaxi
strategi
frequent
approach
addit
high
risk
patient
like
receiv
prolong
cmv
prophylaxi
despit
variou
approach
prevent
cmv
diseas
activ
infect
occur
transplant
recipi
treatment
option
includ
common
commun
approxim
gener
popul
demonstr
serolog
evid
prior
infect
herpesvirus
remain
latent
primari
infect
frequent
reactiv
transplant
howev
signific
reactiv
uncertain
reliabl
associ
specif
clinic
syndrom
infect
commonli
asymptomat
enceph
hepat
gastroduoden
pancytopenia
describ
cmv
prophylaxi
appear
prevent
reactiv
limit
clinic
treatment
data
avail
ganciclovir
valganciclovir
foscarnet
appear
activ
laboratori
test
may
role
reduct
immunosuppress
specif
infect
control
measur
requir
like
infect
common
commun
reactiv
occur
follow
transplant
howev
clinic
import
uncertain
syndrom
regularli
associ
viru
reason
laboratori
perform
pcr
minim
anecdot
data
control
trial
treatment
although
anticmv
drug
ganciclovir
foscarnet
cidofovir
may
effect
specif
infect
control
procedur
requir
along
ebv
oncogen
cancercaus
herpesviru
clinic
manifest
includ
kaposi
sarcoma
ks
bodi
caviti
lymphoma
castleman
diseas
rare
lymphoprolif
disord
preval
vari
greatli
north
america
northern
europ
region
subsaharan
africa
southern
mediterranean
viru
endem
previous
recogn
uncommon
malign
elderli
mediterranean
men
african
children
ashkenazi
jew
ks
becam
common
neoplasm
patient
hiv
infect
incid
time
gener
popul
seroposit
transplant
recipi
small
risk
reactiv
latent
viru
donorderiv
infect
infrequ
report
ks
common
manifest
bodi
caviti
lymphoma
castleman
diseas
rare
present
diagnosi
reactiv
gener
pcr
whilst
ks
bodi
caviti
lymphoma
castleman
diseas
requir
histolog
diagnosi
treatment
antivir
drug
appear
clinic
effect
mainstay
treatment
includ
reduct
immunosuppress
revers
underli
immun
defici
chemotherapi
rituximab
castleman
diseas
specif
infect
control
procedur
requir
respiratori
virus
circul
within
commun
season
geograph
variabl
seriou
complic
uncommon
nonimmunocompromis
host
set
lung
transplant
respiratori
viru
infect
associ
secondari
bacteri
infect
acut
reject
chronic
graft
dysfunct
increas
suscept
respiratori
virus
lung
transplant
recipi
multifactori
includ
immunosuppress
impair
cough
reflex
poor
mucociliari
clearanc
alter
lymphat
drainag
direct
exposur
lung
allograft
environ
prospect
studi
compar
lung
transplant
recipi
respiratori
viru
infect
uninfect
recipi
demonstr
respiratori
viru
infect
greater
risk
acut
reject
bronchiol
obliteran
syndrom
death
import
respiratori
virus
includ
respiratori
viral
infect
common
lung
transplant
recent
studi
lung
transplant
recipi
year
period
found
infect
rate
one
viral
infect
studi
period
asymptomat
carriag
uncommon
mainli
associ
coronavirusrhinoviru
hospitalis
rate
influenza
parainfluenza
virus
infect
control
precaut
respiratori
virus
includ
droplet
precaut
singl
room
mask
gown
glove
room
entri
asymptomat
hand
hygien
per
moment
staff
come
work
respiratori
ill
unwel
visitor
allow
patient
contact
chemoprophylaxi
may
administ
patient
follow
exposur
appropri
see
specif
virus
mani
microbiolog
laboratori
perform
respiratori
pathogen
pcr
diagnost
panel
includ
common
respiratori
virus
influenza
influenza
b
enteroviru
rhinoviru
coronaviru
hmpv
parainfluenza
adenoviru
rsv
nonvir
organ
includ
bordetella
pertussi
bordetella
parapertussi
mycoplasma
pneumonia
pneumocysti
jirovecii
test
gener
perform
nose
throat
swab
requir
nasopharyng
aspir
bronchial
wash
like
mani
respiratori
virus
rsv
season
winter
predomin
healthi
adult
rsv
usual
associ
mild
selflimit
infect
lung
transplant
recipi
rsv
caus
bronchiol
pneumonia
respiratori
failur
signific
acut
mortal
declin
lung
function
associ
subsequ
develop
progress
bronchiol
obliteran
syndrom
bo
rsv
also
associ
acut
reject
recent
prospect
studi
fail
confirm
find
ribavirin
nucleosid
analogu
broad
rang
activ
mani
rna
virus
despit
lack
randomis
trial
data
cornerston
treatment
rsv
ribavirin
administ
way
oral
intraven
aerosolis
neg
pressur
room
specif
equip
requir
advic
regard
administr
dose
regimen
sought
ribavirin
signific
toxic
primarili
haematolog
teratogen
long
halflif
standard
droplet
precaut
requir
patient
manag
singl
room
influenza
season
viru
greatest
incid
infect
winter
month
although
detect
yearround
commun
two
frequent
type
influenza
follow
influenza
b
influenza
virus
characterist
undergo
antigen
drift
minor
annual
chang
surfac
glycoprotein
allow
reinfect
due
inadequ
immun
everi
year
antigen
shift
occur
secondari
reassort
gene
speci
major
outbreak
influenza
occur
time
littl
immun
present
commun
rate
influenza
higher
lung
transplant
solid
organ
transplant
may
commun
acquir
nosocomi
donorderiv
infect
complic
viral
bacteri
pneumonia
occur
frequent
gener
popul
annual
vaccin
transplant
recipi
transplant
candid
famili
strongli
recommend
although
antibodi
respons
may
impair
immunosuppress
patient
treatment
initi
transplant
patient
suspect
proven
influenza
ceas
altern
diagnosi
made
therapeut
option
includ
oseltamivir
oral
influenza
b
zanamivir
inhal
influenza
b
amantadin
oral
influenza
rimantadin
oral
influenza
chemoprophylaxi
offer
patient
known
expos
influenza
viru
either
hospit
commun
set
droplet
standard
precaut
durat
symptom
day
activ
influenza
treatment
parainfluenza
virus
piv
consist
group
serotyp
piv
circul
yearround
commun
caus
varieti
clinic
present
common
cold
bronchiol
pneumonia
piv
associ
larg
hospit
outbreak
infect
due
persontoperson
transmiss
especi
haematolog
ward
mortal
rate
outbreak
lung
transplant
recipi
piv
infect
lead
loss
lung
function
bronchiol
obliteran
syndrom
figur
show
extens
interstiti
pneumonia
patient
sever
piv
infect
randomis
studi
antivir
therapi
howev
report
publish
primarili
haematolog
set
suggest
ribavirin
either
oral
intraven
administ
may
effect
treatment
small
singl
centr
studi
rsv
piv
lung
transplant
recipi
indic
lung
transplant
patient
lower
respiratori
tract
paramyxovir
infect
treat
inhal
ribavirin
die
return
baselin
lung
function
droplet
standard
precaut
hmpv
first
describ
recent
increasingli
recognis
season
predominantli
late
winter
respiratori
pathogen
caus
upper
lower
respiratori
tract
infect
school
age
children
antibodi
viru
indic
widespread
natur
hmpv
hmpv
close
relat
rsv
lung
transplant
recipi
thought
result
graft
dysfunct
howev
mainli
anecdot
data
support
recent
review
dosanjh
conduct
literatur
search
identifi
case
hmpv
allograft
reject
within
month
initi
infect
lung
transplant
recipi
total
sampl
identifi
hmpv
without
coinfect
agent
result
studi
indic
acut
hmpv
infect
without
coinfect
associ
acut
cellular
reject
within
month
case
subsequ
develop
chronic
allograft
dysfunctionbronchiol
obliteran
syndrom
suggest
hmpv
import
pathogen
lung
transplant
set
ribavirin
shown
activ
hmpv
vitro
anim
model
infect
howev
human
studi
hmpv
infect
perform
use
ribavirin
remain
controversi
case
report
support
ribavirin
therapi
concomit
intraven
immunoglobulin
ivig
improv
symptom
droplet
standard
precaut
coronaviru
rhinoviru
frequent
caus
common
cold
gener
popul
howev
immunocompromis
patient
virus
caus
pneumonia
may
fatal
particularli
bone
marrow
transplant
recipi
persist
rhinoviru
infect
associ
graft
dysfunct
describ
lung
transplant
recipi
specif
treatment
option
avail
decreas
immunosuppress
may
role
littl
data
support
droplet
standard
precaut
adenovirus
consist
larg
group
dna
virus
type
known
caus
varieti
ill
includ
gastroenter
enceph
hepat
haemorrhag
cystiti
upper
lower
respiratori
infect
conjunct
immunosuppress
patient
adenoviru
infect
develop
time
transplant
associ
signific
morbid
mortal
rate
adenoviru
infect
report
associ
organ
reject
follow
cardiac
renal
transplant
bridg
et
al
report
patient
adenoviru
infect
alon
develop
bronchiol
obliteran
syndrom
graft
failur
